High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis

Journal of Autoimmunity

Volumn 31, Issue 2, 2008, Pages 91-97

  Yeh, Steven ^a   Wroblewski, Keith ^a   Buggage, Ronald ^a   Li, Zhuqing ^a   Kurup, Shree K ^a   Sen, Hatice Nida ^a   Dahr, Sam ^a   Sran, Pushpa ^a   Reed, George F ^b   Robinson, Randy ^c   Ragheb, Jack A ^a   Waldmann, Thomas A ^d   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PROTEIN DESIGN LABS INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Daclizumab; Interleukin 2; Intermediate uveitis; Panuveitis; Posterior uveitis

Indexed keywords

DACLIZUMAB; LEVOFLOXACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ABDOMINAL CRAMP; ADULT; ANTERIOR EYE CHAMBER; ARTICLE; CHORIORETINOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTERMEDIATE UVEITIS; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; STOMACH PAIN; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS BODY; VOGT KOYANAGI SYNDROME;

ADULT; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 50549090768     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.05.001     Document Type: Article

References (26)

1. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338 3 (1998) 161-165
2. Bumgardner G.L., Hardie I., Johnson R.W., Lin A., Nashan B., Pescovitz M.D., et al. Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72 5 (2001) 839-845
3. Vlad G., Ho E.K., Vasilescu E.R., Fan J., Liu Z., Cai J.W., et al. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol 18 1 (2007) 13-21
4. Mullen J.C., Oreopoulos A., Lien D.C., Bentley M.J., Modry D.L., Stewart K., et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 26 5 (2007) 504-510
5. Lischke R., Simonek J., Davidova R., Schutzner J., Stolz A.J., Vojacek J., et al. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc 39 1 (2007) 205-212
6. Sutherland D.E., Gruessner R.W., Dunn D.L., Matas A.J., Humar A., Kandaswamy R., et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 233 4 (2001) 463-501
7. Rasaiah S.B., Light J.A., Sasaki T.M., and Currier C.B. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression. Clin Transplant 14 4 Pt 2 (2000) 409-412
8. Yoshida E.M., Marotta P.J., Greig P.D., Kneteman N.M., Marleau D., Cantarovich M., et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 11 9 (2005) 1064-1072
9. Figueras J., Prieto M., Bernardos A., Rimola A., Suarez F., de Urbina J.O., et al. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 19 8 (2006) 641-648
10. Waldmann T.A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26 25 (2007) 3699-3703
11. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 96 13 (1999) 7462-7466
12. Nussenblatt R.B., Thompson D.J., Li Z., Chan C.C., Peterson J.S., Robinson R.R., et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21 3 (2003) 283-293
13. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T., and Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140 3 (2005) 509-516
14. Nussenblatt R.B., Palestine A.G., Chan C.C., and Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92 4 (1985) 467-471
15. Buggage R.R., Levy-Clarke G., Sen H.N., Ursea R., Srivastava S.K., Suhler E.B., et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 15 2 (2007) 63-70
16. Caspi R.R., Roberge F.G., Chan C.C., Wiggert B., Chader G.J., Rozenszajn L.A., et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 140 5 (1988) 1490-1495
17. Guex-Crosier Y., Raber J., Chan C.C., Kriete M.S., Benichou J., Pilson R.S., et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 158 1 (1997) 452-458
18. McDyer J.F., Li Z., John S., Yu X., Wu C.Y., and Ragheb J.A. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol 169 5 (2002) 2736-2746
19. Li Z., Lim W.K., Mahesh S.P., Liu B., and Nussenblatt R.B. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174 9 (2005) 5187-5191
20. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103 15 (2006) 5941-5946
21. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13 6 (2007) 711-718
22. Schmidt-Weber C.B., Akdis M., and Akdis C.A. TH17 cells in the big picture of immunology. J Allergy Clin Immunol 120 2 (2007) 247-254
23. Kiss S., Ahmed M., Letko E., and Foster C.S. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 112 6 (2005) 1066-1071
24. Gallagher M., Quinones K., Cervantes-Castaneda R.A., Yilmaz T., and Foster C.S. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 91 10 (2007) 1341-1344
25. Papaliodis G.N., Chu D., and Foster C.S. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110 4 (2003) 786-789
26. Nussenblatt R.B., Peterson J.S., Foster C.S., Rao N.A., See R.F., Letko E., et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112 5 (2005) 764-770